Needham & Company LLC Reaffirms “Buy” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Needham & Company LLC reissued their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note issued to investors on Thursday, Benzinga reports. Needham & Company LLC currently has a $200.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the stock. William Blair restated an outperform rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Morgan Stanley dropped their price objective on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an equal weight rating on the stock in a report on Tuesday, February 13th. Chardan Capital reduced their target price on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a buy rating for the company in a research note on Friday, February 16th. HC Wainwright reissued a buy rating and set a $395.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, March 5th. Finally, The Goldman Sachs Group cut Alnylam Pharmaceuticals from a buy rating to a neutral rating and cut their price target for the company from $230.00 to $173.00 in a report on Friday, February 16th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus target price of $215.88.

Alnylam Pharmaceuticals Trading Up 1.3 %

Alnylam Pharmaceuticals stock traded up $2.02 on Thursday, reaching $152.33. 452,157 shares of the stock were exchanged, compared to its average volume of 763,489. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $218.88. The firm has a fifty day moving average price of $149.76 and a two-hundred day moving average price of $165.25. The stock has a market cap of $19.19 billion, a PE ratio of -42.22 and a beta of 0.41.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.40) EPS. Equities analysts anticipate that Alnylam Pharmaceuticals will post -4.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its position in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares in the last quarter. Quent Capital LLC raised its stake in shares of Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 123 shares during the last quarter. Anchor Investment Management LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $38,000. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 12,513 shares in the last quarter. Finally, GAMMA Investing LLC bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $52,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.